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Background: Myocardial ischemia-reperfusion injury is a main cause of postoper-
ative cardiac dysfunction, and a burst of proinflammatory cytokines, such as tumor
necrosis factor , interleukin 1, interleukin 6, and interleukin 8, plays a pivotal
role. Recently, JTE-607 has been reported as a potent inhibitor of the multiple
inflammatory cytokines in the endotoxin shock mouse model. In this study we
proved the hypothesis that JTE-607 might attenuate myocardial ischemia-reperfu-
sion injury in a rat model.
Methods: The isolated rat hearts in the JTE-607 preconditioning group (J group, n
 8) or control group (C group, n 8) were subjected to warm ischemia (37°C) for
30 minutes, followed by 60 minutes of reperfusion with the Langendorff perfusion
system.
Results: Left ventricular developed pressure and maximum dp/dt after reperfusion
were significantly improved in the J group than in the C group (P  .01). Creatine
phosphokinase leakage is significantly lower in the J group (P .05). Moreover, the
tissue cytokine levels, such as tumor necrosis factor , interleukin 6, and interleukin
8, in the myocardium were significantly lower in the J group than in the C group (P
 .05).
Conclusion: These results suggested that the pharmacologic preconditioning of
JTE-607 inhibits a burst of endogenous cytokines in the myocardium, resulting in
the improvement of cardiac function after ischemia-reperfusion injury. Thus JTE-
607 might be a novel therapeutic strategy for the protection of postoperative cardiac
dysfunction in cardiac surgery.
Recent advances in myocardial protection have improved the clinicalresults in cardiac surgery. However, severely critical cases associ-ated with a compromised heart, such as a failing heart or postisch-emic conditions, still occur, and thus further attempts to improvemyocardial protection should be addressed.1
Recent studies have shown that proinflammatory cytokines (tumor necrosis
factor [TNF] , interleukin [IL] 1, IL-6, and IL-8) induced by ischemia-reperfu-
sion injury lead to myocardial dysfunction, either directly or through the adherence
of neutrophils to endothelial cells.2,3 Therefore several studies to attenuate cytokine-
induced ischemia-reperfusion injury have been reported. However, no studies have
reported inhibition for the broad spectrum of inflammatory cytokines, and few
attempts at chronic application have been made.4
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JTE-607, an N-benzoyl-L-phenylalanine–derived com-
pound, is a multiple-cytokine inhibitor that strongly sup-
presses production of proinflammatory cytokines, such as
IL-8, IL-1, and TNF- from lipopolysaccharide (LPS)–
stimulated peripheral blood mononuclear cells by reducing
the increase in the level of mRNAs of these cytokines.5
Although the activity is 100 to 1000 times lower in rodents
compared with in human subjects, JTE-607 protects mice
from LPS-induced endotoxin shock in accordance with a
decrease in plasma TNF- levels and also protects against
LPS-induced acute lung injury through chemotactic cyto-
kine inhibition, such as cytokine-induced neutrophil che-
moattractant (CINC-1) from alveolar macrophages.6 More-
over, JTE-607 can be immediately absorbed by almost
every organ, including the heart, by means of intravenous or
intraperitoneal injection, and the half-life is about 30 min-
utes. Therefore this drug is suited for preconditioning of the
heart subjected to ischemia and reperfusion. Therefore it is
expected that pharmacologic preconditioning with JTE-607
might attenuate ischemia-reperfusion injury in the myocar-
dium by suppressing the production of inflammatory cyto-
kines in a preclinical trial.
In this study we investigated whether the pharmacologic
preconditioning of JTE-607 might attenuate ischemia-reper-
fusion injury in an isolated rat heart model.
Methods
Test Compounds
JTE-607, ()-ethyl-N-{3-5-dichloro-2-hydroxy-4-[2-(4-methylpi-
perazin-1-yl)]ethoxybenzoyl}-L-phenylalanine dihydrochloride, was
provided by Japan Tobacco, Osaka, Japan. JTE-607 was dissolved
and diluted in 5% mannitol before use.
Pharmacologic Preconditioning and Rat Ischemia
Model
Sixteen Sprague-Dawley rats (300 g, male) were used for this
study. Humane animal care complied with the “Principle of Lab-
oratory Animal Care” formulated by the National Society for
Medical Research and the “Guide for the Care and Use of Labo-
ratory Animals” prepared by the Institute of Laboratory Animal
Resources and published by the National Institutes of Health
(National Institutes of Health publication No. 85-23, revised
1996). The rats were divided into the control group (C group, n 
8) and the JTE group (J group, n  8). All rats were anesthetized
by means of intraperitoneal injection of sodium pentobarbital (50
mg/kg), and 0.5 mL of saline (C group) or 0.1 mg/kg of JTE-607
dissolved in the same volume of 5% mannitol (J group) was
injected intraperitoneally. Ten minutes after the injection and
anticoagulation with heparin (200 USP units, intraperitoneally),
the hearts were quickly excised in Krebs-Henseleit buffer (120.0
mmol/L NaCl, 4.5 mmol/L KCl, 20.0 mmol/L NaHCO3, 1.2
mmol/L KH2PO4, 1.2 mmol/L MgCl2, 2.5 mmol/L CaCl2, and
10.0 mmol/L glucose gassed with 95% O2  5% CO2 to obtain a
Figure 1. Cardiac function before and after ischemia. A, LVDP before and after ischemia. Better recovery of LVDP
after ischemia was shown in the J group than in the C group. B, Maximum dP/dt before and after ischemia. Better
recovery of maximum dP/dt after ischemia was shown in the J group than in the C group. *P < .05, n  8 in each
group. All values are expressed as means  SEM.
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pH of 7.4 at 37°C) at a pressure equal to 1 m of H2O by means of
a Langendorff apparatus. A thin-wall latex balloon was inserted
into the left ventricle through the left atrium to monitor left
ventricular pressure and to control left ventricular volume. After
stabilization, heart rate, left ventricular developed pressure
(LVDP), maximum dp/dt, and coronary flow were measured, with
left ventricular diastolic pressure stabilized at 10 mm Hg. The
hearts were then subjected to global ischemia at 37°C for 30
minutes, followed by 60 minutes of reperfusion. The balloon was
deflated during ischemia, and the hearts were not paced during
reperfusion. The indices of cardiac function were continuously
measured after reperfusion and analyzed (Polygraph System, Ni-
hon Kouden, Japan). The coronary effluent was collected in chilled
vials to measure creatine phosphokinase (CPK) levels after reper-
fusion.
After 60 minutes of reperfusion, frozen sections of the hearts
were made and stored at 80°C for further assessment.
Myocardial Water Content
The basal region of the heart was taken and weighed to evaluate
myocardial water content after reperfusion. Next, it was desiccated
at 96°C for 24 hours and then reweighed. The myocardial water
content was calculated by using the following formula: Myocardial
water content (1  dry weight/wet weight) 100 (%).
Enzyme-Linked Immunosorbent Assay for
Inflammatory Cytokines
After 60 minutes of reperfusion, the frozen tissue samples were
homogenized with a Polytron homogenizer (Brinkmann Instru-
ments, Westbury, NY) and centrifuged. The concentration of tissue
inflammatory cytokines was measured with enzyme-linked immu-
nosorbent assay kits (TNF-, IL-1, and IL-6: Biosource Interna-
tional, Camarillo, Calif; IL-8: Immuno-Biological Laboratories,
Gunma, Japan), according to the manufacturer’s recommendation.
Statistical Analysis
All data are expressed as means  SEM. The differences in the
data on functional recoveries were determined with 1-way repeat-
ed-measures analysis of variance, and those on CPK leakage and
tissue cytokine concentrations were determined with the unpaired
Student t test.
Results
Recovery of Cardiac Function After Global Ischemia
Cardiac function was analyzed before and after global warm
ischemia and reperfusion. In this experiment no significant
differences in heart rate, LVDP, maximum dp/dt, or coro-
nary flow were seen before global ischemia in the 2 groups.
The time course of percentage recovery of LVDP and
maximum dP/dt after global ischemia (37°C for 30 minutes)
was shown in Figure 1. The hearts of the J group showed
significantly better recoveries of LVDP or maximum dP/dt
than the C group. The peak values of the recovery rate of
LVDP and maximum dP/dt were 79%  5% and 80% 
4% in the J group and 39%  6% and 54%  7% in the C
group (P  .05).
CPK leakage of the coronary effluent was significantly
lower in the J group compared with that in the C group (2.9
 2.0 vs 1.4 102 61 IU/60 minutes, P .05, Figure 2).
Myocardial Water Content
No significant difference of the myocardial water content
was found between the 2 groups (J group: 80%  2% vs C
group: 81%  2%).
Tissue Amounts of Inflammatory Cytokines
The tissue level of TNF- was significantly lower in the J
group compared with that in the C group (2.4  0.3  102
vs 5.5 0.8 102 pg/mg tissue, P .05; Figure 3, A). The
tissue level of IL-6 was significantly lower in the J group
compared with that in the C group (60  7 vs 3.0  0.8 
102 pg/mg tissue, P  .05; Figure 3, B). The tissue level of
IL-8 was significantly lower in the J group compared with
that in the C group (68  19 vs 2.4  0.4  102 pg/mg
tissue, P  .05; Figure 3, C). The tissue level of IL-1 was
lower in the J group compared with that in the C group (2.6
 0.2 103 vs 3.7 0.7 102 pg/mg tissue; Figure 3, D).
Discussion
In the present report we showed a cardioprotective effect of
pharmacologic preconditioning with JTE-607, a novel cy-
tokine synthesis inhibitor. The recovery of cardiac function
of hearts after reperfusion was significantly better in the
JTE-607 preconditioning group. In addition, the JTE-607
preconditioning group showed significantly lower levels of
Figure 2. Suppression of leakage of CPK from the cardiac myo-
cytes in the hearts of J group compared with those of C group.
CPK activity was measured in the coronary effluent for 60 minutes
after reperfusion. *P < .05. All values are expressed as means 
SEM.
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CPK leakage of coronary flow and significantly lower levels
of tissue inflammatory cytokines (TNF-, IL-6, and IL-8).
These data were not influenced by myocardial edema be-
cause no significant difference was found in the myocardial
water content. These results suggested that the pharmaco-
logic preconditioning of JTE-607 inhibits a burst of cyto-
kines in the myocardium, resulting in the attenuation of
ischemia-reperfusion injury.
Although previous studies have shown that proinflam-
matory cytokines have direct effects for the decrease of
myocardial contractility,7,8 the characteristics of each cyto-
kine to the myocardium widely differ. IL-1 was shown to
blunt the positive inotropic response to isoproterenol in
neonatal cardiac myocytes but in the delayed phase (72
hours).9 IL-6 had been considered to have negative inotro-
pic effects on the basis of evidence of increased level of
IL-6 linked to cardiac dysfunction after cardiopulmonary
bypass,10-12 but recently, IL-6 has been considered to be a
marker rather than a critical mediator of myocardial inju-
ry.13 IL-8 is known to be a potent chemoattractant for
neutrophils to induce reperfusion injury,14,15 but no evi-
dence has been reported that IL-8 in itself has an effect for
myocardial contractility. As opposed to these proinflamma-
tory cytokines, TNF- can induce myocardial decrease
within minutes through the production of sphingosine,16 a
depressant of calcium transient in the myocardium. More-
over, TNF- was shown to be induced by ischemia-reper-
fusion injury in the crystalloid-perfused heart,17 and the
origin of this cytokine suggested that it is derived from
resident monocytes-macrophages in the myocardium or the
myocyte itself.18 Together with this evidence and our results
on the immediate effect of JTE-607 in the crystalloid-
perfused heart, the supposed mechanism of the cardiopro-
tective effect of JTE607 might be mainly the inhibition of
TNF- derived from resident monocytes-macrophages in
the myocardium or the myocyte. Further in vitro study will
be needed to confirm this mechanism.
Although we demonstrated that the inhibition of myo-
cardial tissue cytokine can improve function, it does not
reflect in vivo conditions in many ways. Because this heart
model is perfused with crystalloid and not blood, aspects of
blood that are either protective (ie, antioxidant) or injurious
(ie, neutrophils and blood-derived cytokines) do not con-
tribute.17 Indeed, we have already performed a blood per-
Figure 3. Tissue level of inflammatory cytokines in the myocardium after reperfusion. The levels of TNF-, IL-6, and
IL-8 were significantly lower in the J group than in the C group (a, b, and c). The level of IL-1 has no significant
difference (d). *P < .05. All values are expressed as means  SEM.
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fusion model with a rat cardiopulmonary bypass model and
found significant improvement of respiratory function and
the significant inhibition of blood IL-8 after cardiopulmo-
nary bypass by means of the injection of JTE-607 (unpub-
lished data). After coupling these results and our findings, it
is suggested that JTE-607 might be effective for cardiac
surgery by inhibiting proinflammatory cytokines both in the
myocardium and in the blood. Therefore further studies are
required to examine the cardioprotective effect of JTE-607
with a blood-perfused ischemia-reperfusion model to inves-
tigate how JTE-607 influences the factors in the blood. In
conclusion, we obtained evidence that JTE-607 attenuates
myocardial ischemia-reperfusion injury through inhibition
of synthesis of inflammatory cytokines. Thus JTE-607
might be a novel therapeutic strategy for the protection of
postoperative cardiac dysfunction in cardiovascular surgery.
We thank Hiromitsu Watanabe (Japan Tobacco Inc) for pro-
viding current data and information about JTE-607.
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